影像诊断MASLD但活检脂肪变分级S0的特征与结局
研究探讨影像诊断MASLD而肝活检脂肪变S0(steatosis 0)患者的结局与原因。随访队列3273例中123例(3.8%)为steatosis 0,其中29.3%有进展期纤维化(燃尽型MASLD)且存在肝脏相关事件风险。配对活检队列1865例中74例(4.0%)初始S0,93.2%随访仍无或轻度脂肪变;MRI-PDFF显示肝脂肪分布不均,病理评估差异可致误分类。
要点
- 影像诊断MASLD而活检S0者占3.8%,其中29.3%有进展期纤维化(燃尽型MASLD)。
- 无进展期纤维化的steatosis 0患者随访无肝脏相关事件。
- steatosis 0可能源于燃尽型MASLD、肝脂肪分布不均或病理评估差异。
核心结论
- steatosis 0是MASLD诊断中的潜在灰区,可能由燃尽型MASLD、肝脂肪分布不均或病理评估差异导致。
研究设计与样本
- 研究使用全球队列评估结局、配对活检的组织学进展及可能原因。
- 随访队列纳入16个中心3273例接受活检的个体。
- 配对活检队列纳入1865例患者。
- 原因分析包括42例MASLD患者的MRI-PDFF评估、病理学家一致性检测及连续活检切片比较。
主要发现
- 随访队列中123例(3.8%)表现为steatosis 0。
- steatosis 0患者中29.3%有进展期纤维化(燃尽型MASLD)并显示肝脏相关事件风险。
- 无进展期纤维化的steatosis 0患者无肝脏相关事件。
- 配对活检队列中74例(4.0%)初始为S0,其中93.2%随访活检仍无或轻度脂肪变。
- 42例MASLD患者的MRI-PDFF显示肝脂肪分布不均,部分节段呈S0但平均肝脂肪升高。
关键数值与推荐
- steatosis 0定义为影像检测的MASLD且活检脂肪变分级为S0。
临床怎么用
- 对影像诊断MASLD但活检S0者,应警惕进展期纤维化(燃尽型MASLD)可能。
- 需考虑肝脂肪分布不均和病理评估差异对分级的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease, and liver biopsy remains the gold standard for diagnosis. However, a subset of patients diagnosed with MASLD by imaging paradoxically exhibit steatosis grade S0 on liver biopsy, posing a diagnostic challenge. This study investigated the outcomes and causes of steatosis 0. METHODS: Steatosis 0 was defined as imaging-detected MASLD with a biopsy-defined steatosis grade S0. We used global cohorts to evaluate outcomes, histologic progression by paired biopsies, and possible causes. The cause analysis included MRI-proton density fat fraction (MRI-PDFF) for fat distribution, pathologist consistency testing, and comparison of serial biopsy sections. RESULTS: In a follow-up cohort of 3,273 biopsy individuals from 16 centers, 123 (3.8%) exhibited steatosis 0. Of these, 29.3% of them had advanced fibrosis (burnt-out MASLD) and demonstrated a risk of liver-related events, whereas those without advanced fibrosis had no such events. In the paired-biopsy cohort of 1,865 patients, 74 (4.0%) individuals initially showed steatosis grade S0; among them, 93.2% retained no or mild steatosis on follow-up biopsy. MRI-PDFF assessments in 42 MASLD patients revealed heterogeneous hepatic fat distribution, with some segments showing steatosis grade S0 despite elevated average liver fat. Interpathologist variability and discrepancies across consecutive biopsy sections contributed to misclassification of steatosis grade. DISCUSSION: Steatosis 0 represents a potential diagnostic gray zone in MASLD. It may be caused by burnt-out MASLD, uneven liver fat distribution, or variability in pathological assessment. Understanding the causes and implications of steatosis 0 is critical for diagnosis and management.
引用
- Liu WY, Lian LY, Kim SU, et al. Characteristics and Outcomes of Patients With Imaging-Defined MASLD and Histological Steatosis Grade S0. Am J Gastroenterol. 2026. PMID: 42467969. doi:10.14309/ajg.0000000000004116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。